All News

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
COVID,teen,young,man,mask

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children

Jack Cush, MD

Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.

Read Article
fever2.jpg

When to Stop Biologics in Systemic JIA?

Jack Cush, MD

Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.

Read Article
rare

Risks associated with mortality in VEXAS

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Jack Cush, MD

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-DRB1*15 haplotypes.

Read Article
UTSW Rheum Grand Rounds MAS occurs in 2-8% of Systemic JIA pts and has a high mortality (<40%); It is more frequent w/ onset in Years 1-4. Treatment - steroids, anakinra, etoposide or CsA & Rx infxn if present. Oh...dont stop the anakinra! @UTSWRheum https://t.co/09uQm3LURC
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds IL-18 levels are elevated in systemic JIA, MAS and AOSD @UTSWRheum https://t.co/pIYKf4pods
Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds with Dr. Peter Nigrovic on systemic JIA in children and adults; yes, its the same disease with the same features. @UTSWRheum https://t.co/C7eBFjnDIi
Dr. John Cush RheumNow ( View Tweet)
Biomarker study of 21 systemic juvenile idiopathic arthritis (sJIA) shows you can differentiate between active & inactive disease. From 69 biomarkers, these were predictive: IL-6, MMP1, S100A12 (p < 0.0001), HMGB1; but IL-18 elevated in both groups! https://t.co/m2yXTITzwY

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center comparison of pts with MAS vs malignancy assoc. HLH (mHLH) - overall MAS had less hepatomegaly (0 v 25%), double platelet #s (50 v 29Kµ/L), but lower sIL-2R (6814 vs. 27,972.0) and less mortality (22 v 44%, p=0.18). https://t.co/NGIaPTU0yT

Links:

Dr. John Cush RheumNow ( View Tweet)

There have been reports of COVID-19 vaccination causing adult-onset Still’s dz onset. Now a case of AOSD, given the BNT162b2 vax and developing Macrophage activation syndrome w/ ferritin levels of 136,680 µg/l https://t.co/caKef9BGDR

Links:

Dr. John Cush RheumNow ( View Tweet)

Of 173 autoimmune inflammatory rheumatic Dz pts w/ respiratory Sx, 46 had Pneumocystis jirovecii. Higher risk of PJP w/ high-dose steroids, recent immunosuppressives, combo w/ CsA, hx of chr lung dz, high LDH, ground glass CXR https://t.co/P8KtC2Hab8

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Risks associated with mortality in VEXAS https://t.co/mpAc5shaMq https://t.co/FdOQcfwusp

Links:

Dr. John Cush RheumNow ( View Tweet)

Download Available! AOSD Disease Patterns Over Time https://t.co/qZBtCQ2QAg https://t.co/fMmN1PAzFG

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting. https://t.co/oafDX0rJIl https://t.co/UoNpjABLNd

Links:

Dr. John Cush RheumNow ( View Tweet)

New Download Available! AOSD Disease Patterns Over Time https://t.co/IYePF20Nkn https://t.co/fOnc6jUl1b

Links:

Dr. John Cush RheumNow ( View Tweet)
Flare Patterns in Autoinflammatory Syndrome During Pandemic: Dr. Yuz Yusof ( @Yuz6Yusof) discusses abstract #1083 presented at the #ACR21 annual meeting. https://t.co/i0VU3NEe7F https://t.co/DZkB5TgG3N

Links:

Dr. John Cush RheumNow ( View Tweet)

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares Drs.Cush, Yusof, Mehta, Petryna and Tate review autoinflammatory data presented at #ACR21. @Yuz6Yusof @bella_mehta @DrPetryna @uptoTate https://t.co/oeAprkSBWZ https://t.co/1g9yRRFJqf

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 is complete--view all our RheumNow's coverage. https://t.co/wkZ66lcB44

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×